MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...
An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...
Live Science on MSN6d
Are you protected against measles? Do you need a booster shot? Everything you need to know about immunityThere have been hundreds of measles cases reported in the U.S. since the beginning of the year. Here's what you need to know ...
The following is a summary of “Kinetics of tick-borne encephalitis virus IgM antibody responses in serum and cerebrospinal ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...
Hosted on MSN11d
New antibody reduces tumor growth in tough-to-treat breast and ovarian cancers: StudyHER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...
Recent study conducted by Caushi et al. aimed to evaluate the role of Elisa IgG serum antibody titres in diagnosing pulmonary ...
Michigan has confirmed its first measles case since last July. An Oakland County adult tested positive after recently ...
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback